Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 12,585,141	$ 16,595,689
General and administrative	25,703,731	11,248,372
Total operating expenses	38,288,872	27,844,061
Loss from operations	(38,288,872)	(27,844,061)
Interest income (expense)	(1,343,439)	(1,415,909)
Net loss	$ (39,632,311)	$ (29,259,970)
Net loss per common share, basic and diluted	$ (1.03)	$ (0.78)
Weighted average common shares outstanding, basic and diluted	38,323,167	37,429,450